Literature DB >> 20880875

Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis.

Martina Ulrich1, Isabelle Beer, Peter Braitmaier, Michaela Dierkes, Florian Kummer, Bernhard Krismer, Ulrike Schumacher, Ute Gräpler-Mainka, Joachim Riethmüller, Peter Ø Jensen, Thomas Bjarnsholt, Niels Høiby, Gabriel Bellon, Gerd Döring.   

Abstract

BACKGROUND: Patients with cystic fibrosis (CF) with Pseudomonas aeruginosa lung infections produce endobronchial mucus plugs allowing growth of obligate anaerobes including Prevotella spp. Whether obligate anaerobes contribute to the pathophysiology of CF lung disease is unknown.
METHODS: The virulence of Prevotella intermedia and Ps aeruginosa was investigated in vitro and in mice, antibodies against P intermedia in CF sera were assessed and a culture-independent detection method for P intermedia/P nigrescens in CF sputum was tested.
RESULTS: P intermedia reached cell numbers of >10(5)->10(7) colony-forming units (CFU)/ml sputum. The majority of patients with CF (16/17; 94.1%) produced antibodies against two immunoreactive antigens of P intermedia. Culture supernatant fluids, collected from 10(9) P intermedia cells, were more cytotoxic to respiratory epithelial cells in vitro and inflammatory in mouse lungs than respective fluids from anaerobically grown Ps aeruginosa, while fluids from aerobically grown Ps aeruginosa had the highest cytotoxicity and inflammation. Both pathological effects were largely reduced when culture supernatant fluids from 10(7) cells of either species were used. P intermedia cells (∼10(6)CFU/lung) did not induce mortality in the agar beads lung infection mouse model, while Ps aeruginosa cells caused death in 30% of mice due to rapid multiplication. A P intermedia/P nigrescens-specific PNA probe was significantly more sensitive than culture-dependent diagnostic assays to detect these strict anaerobes.
CONCLUSION: Ps aeruginosa and P intermedia become significantly virulent in vitro and in vivo when cell numbers exceed 10(8) CFU/lung.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20880875     DOI: 10.1136/thx.2010.137745

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  32 in total

Review 1.  Cystic fibrosis papers of the year 2010-2011.

Authors:  David Honeybourne
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

2.  In vitro effects of N-acetyl cysteine alone and in combination with antibiotics on Prevotella intermedia.

Authors:  Ji-Hoi Moon; Eun-Young Jang; Kyu Sang Shim; Jin-Yong Lee
Journal:  J Microbiol       Date:  2015-05-03       Impact factor: 3.422

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Airway microbiota across age and disease spectrum in cystic fibrosis.

Authors:  Edith T Zemanick; Brandie D Wagner; Charles E Robertson; Richard C Ahrens; James F Chmiel; John P Clancy; Ronald L Gibson; William T Harris; Geoffrey Kurland; Theresa A Laguna; Susanna A McColley; Karen McCoy; George Retsch-Bogart; Kurtis T Sobush; Pamela L Zeitlin; Mark J Stevens; Frank J Accurso; Scott D Sagel; J Kirk Harris
Journal:  Eur Respir J       Date:  2017-11-16       Impact factor: 16.671

5.  Changes in the lung bacteriome in relation to antipseudomonal therapy in children with cystic fibrosis.

Authors:  Lenka Kramná; Pavel Dřevínek; Jake Lin; Michal Kulich; Ondrej Cinek
Journal:  Folia Microbiol (Praha)       Date:  2017-11-10       Impact factor: 2.099

6.  Contribution of Veillonella parvula to Pseudomonas aeruginosa-mediated pathogenicity in a murine tumor model system.

Authors:  Christian Pustelny; Uliana Komor; Vinay Pawar; Anne Lorenz; Agata Bielecka; Annette Moter; Benjamin Gocht; Denitsa Eckweiler; Mathias Müsken; Claudia Grothe; Heinrich Lünsdorf; Siegfried Weiss; Susanne Häussler
Journal:  Infect Immun       Date:  2014-11-10       Impact factor: 3.441

7.  In Vitro Effects of Polyphosphate against Prevotella intermedia in Planktonic Phase and Biofilm.

Authors:  Eun-Young Jang; Minjung Kim; Mi Hee Noh; Ji-Hoi Moon; Jin-Yong Lee
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

Review 8.  Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi.

Authors:  James F Chmiel; Timothy R Aksamit; Sanjay H Chotirmall; Elliott C Dasenbrook; J Stuart Elborn; John J LiPuma; Sarath C Ranganathan; Valerie J Waters; Felix A Ratjen
Journal:  Ann Am Thorac Soc       Date:  2014-10

9.  Prevotella intermedia induces severe bacteremic pneumococcal pneumonia in mice with upregulated platelet-activating factor receptor expression.

Authors:  Kentaro Nagaoka; Katsunori Yanagihara; Yoshitomo Morinaga; Shigeki Nakamura; Tatsuhiko Harada; Hiroo Hasegawa; Koichi Izumikawa; Yuji Ishimatsu; Hiroshi Kakeya; Masaharu Nishimura; Shigeru Kohno
Journal:  Infect Immun       Date:  2013-11-18       Impact factor: 3.441

10.  The Role of Short-Chain Fatty Acids, Produced by Anaerobic Bacteria, in the Cystic Fibrosis Airway.

Authors:  Bojana Mirković; Michelle A Murray; Gillian M Lavelle; Kevin Molloy; Ahmed Abdul Azim; Cedric Gunaratnam; Fiona Healy; Dubhfeasa Slattery; Paul McNally; Joe Hatch; Matthew Wolfgang; Michael M Tunney; Marianne S Muhlebach; Rosaleen Devery; Catherine M Greene; Noel G McElvaney
Journal:  Am J Respir Crit Care Med       Date:  2015-12-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.